NCT01475513View on ClinicalTrials.gov

Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women

PHASE4CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 28, 2014

Study Completion Date

May 28, 2014

Conditions
Insulin SensitivityCardiovascular RiskPerimenopausal Disorder
Interventions
DRUG

Ortho Cyclen®

Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) will be taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.

Trial Locations (1)

23298-0111

Virginia Commonwealth University Medical Center, Richmond

All Listed Sponsors
collaborator

American Heart Association

OTHER

lead

Virginia Commonwealth University

OTHER

NCT01475513 - Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women | Biotech Hunter | Biotech Hunter